Ads
related to: factor viii manufacturers- Dosing Information
Learn more about dosing
with ADYNOVATE®.
- Bleed Protection
Find a Hemophilia A treatment
that’s taken twice weekly.
- Talk to a Representative
Reach out to a Takeda rep
for questions about ADYNOVATE®.
- Access and Resources
Explore downloadable tools
and resources.
- Patient-Reported Outcomes
Learn about patient clinical
outcomes following treatment.
- Patient Resources
Find access to support throughout
your patients' treatment journey.
- Dosing Information
Search results
Results From The WOW.Com Content Network
Octapharma was founded in 1983 by Wolfgang Marguerre, a German businessman who had previously worked in the pharmaceutical industry. The name Octapharma is derived from the Greek word for eight, referring to Factor VIII, the blood clotting protein deficient in patients with haemophilia A.
Coagulation factor VIII (Factor VIII, FVIII, also known as anti-hemophilic factor (AHF)) is an essential blood clotting protein. In humans, it is encoded by F8 gene . [ 5 ] [ 6 ] Defects in this gene result in hemophilia A , an X-linked bleeding disorder .
A purified factor VIII concentrate is made from human blood plasma. [14] A recombinant version is also available. [13] People may develop antibodies to factor VIII such that this medication becomes less effective. [15] Factor VIII was first identified in the 1940s and became available as a medication in the 1960s.
Hemophilia A causes a deficiency in Factor VIII, a protein required for blood clotting. Factor VIII injections are a common treatment to prevent or stop bleeding in people with hemophilia A. [1] Contamination of these and other products caused large numbers of hemophiliacs to become infected with HIV and hepatitis C.
Efanesoctocog alfa is a recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment & control of bleeding episodes; and perioperative management of bleeding.
Treatment and prevention of bleeding episodes is done primarily by replacing the missing blood clotting factors using "synthetic" or "non-human derived" factor products such as recombinant factor VIII. [24] Factor products work by replacing the missing factor proteins, which can take place at home or in hospital. In the 1970s, haemophiliacs ...
Ads
related to: factor viii manufacturers